Probiotics eased adult eczema in pooled trial data

Atopic dermatitis, the most common form of eczema, is an itchy inflammatory skin condition that erodes quality of life, and adults with it have fewer well-evidenced options than the size of the problem deserves. Probiotics have long been proposed as a way to influence the immune system through the gut, but the authors note there has been a lack of certain evidence for their therapeutic efficacy in adult atopic dermatitis specifically. This review set out to pool the randomised trial evidence and, beyond asking whether probiotics help at all, to rank which formulations look most promising.

The researchers searched PubMed, EMBASE and the Cochrane Database for randomised controlled trials of single or mixed probiotic therapy in adults with atopic dermatitis. Nine studies qualified, contributing 402 participants in total: 208 who received probiotic treatments and 194 controls. Changes in disease severity and quality of life were combined using standardised mean differences, a way of putting results measured on different scales onto a common footing. The relative merits of the different probiotic formulations were then ranked using a cumulative probability method to estimate which was most likely to be best.

Probiotic supplementation reduced disease severity compared with controls in both the short term and the long term, with the short-term estimate only narrowly clearing the threshold for statistical significance and the long-term estimate looking more substantial. Long-term quality of life also improved significantly relative to controls. When the formulations were ranked, a mixture of Lactobacillus salivarius LS01 and Bifidobacterium BR03 emerged with the highest probability of being the best supplementation, leading the authors to describe that combination as appearing optimal.

Much of the enthusiasm around probiotics for eczema has run ahead of adult-specific evidence, and this pooling nudges the ledger towards genuine benefit for adults rather than leaving the question entirely open. That said, the evidence base is modest: nine trials and 402 people is a small foundation, and the marginal short-term result means the effect could be fragile. The strain ranking is also indirect, derived from modelling rather than trials pitting mixtures against each other, so which probiotic, at what dose and for how long, all remain unresolved questions for larger head-to-head studies.

For an adult managing eczema, this is a reason to see probiotics as a plausible complementary avenue rather than marketing froth: pooled trial data showed real reductions in severity and better long-term quality of life. It is not a reason to expect dramatic results, and the specific two-strain mixture that topped the ranking earned that position statistically, not by beating rivals directly. Anyone weighing it up should treat this as an evolving evidence base where the direction looks favourable but the details are far from settled.